- Home
- CELC vs KNSA Comparison
CELC vs KNSA Comparison
Compare CELC & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELC | KNSA |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.4B |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CELC | KNSA |
|---|---|---|
| Price | $114.28 | $45.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $106.63 | $55.29 |
| AVG Volume (30 Days) | 527.9K | ★ 599.1K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | N/A | $38.01 |
| Revenue Next Year | N/A | $17.42 |
| P/E Ratio | ★ N/A | $61.55 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $7.58 | $18.26 |
| 52 Week High | $120.32 | $49.12 |
Technical Indicators
Market Signals| Indicator | CELC | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 56.01 | 51.17 |
| Support Level | $97.75 | $40.47 |
| Resistance Level | $114.54 | $46.48 |
| Average True Range (ATR) | 5.14 | 2.12 |
| MACD | 0.36 | -0.09 |
| Stochastic Oscillator | 63.53 | 68.45 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.